LifeStance Health Group (NASDAQ:LFST) Price Target Raised to $17.00

LifeStance Health Group (NASDAQ:LFST) had its target price raised by investment analysts at KeyCorp from $15.00 to $17.00 in a research note issued on Friday, Benzinga reports. The firm presently has an “overweight” rating on the stock. KeyCorp‘s price objective indicates a potential upside of 25.57% from the company’s current price.

Several other research firms also recently weighed in on LFST. Canaccord Genuity Group raised their price target on LifeStance Health Group from $13.00 to $15.00 and gave the stock a “buy” rating in a research report on Wednesday, September 9th. Weiss Ratings upgraded LifeStance Health Group from a “hold (c-)” rating to a “hold (c)” rating in a research report on Tuesday, August 11th. BTIG Research increased their price objective on LifeStance Health Group from $18.00 to $20.00 and gave the company a “buy” rating in a research note on Thursday. Barclays lifted their price objective on LifeStance Health Group from $13.00 to $15.00 and gave the stock an “overweight” rating in a research report on Thursday, September 10th. Finally, Zacks Research cut LifeStance Health Group from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 13th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat, LifeStance Health Group has an average rating of “Moderate Buy” and a consensus target price of $13.62.

LifeStance Health Group Trading Up 0.8%

Shares of LFST opened at $13.54 on Friday. The company has a debt-to-equity ratio of 0.18, a current ratio of 1.38 and a quick ratio of 1.38. The firm has a 50 day simple moving average of $12.59 and a 200-day simple moving average of $9.46. LifeStance Health Group has a 1-year low of $5.87 and a 1-year high of $15.66. The stock has a market cap of $5.17 billion, a price-to-earnings ratio of 105.15 and a beta of 1.35.

LifeStance Health Group (NASDAQ:LFST) last issued its quarterly earnings data on Thursday, November 5th. The company reported $0.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.04 by $0.02. LifeStance Health Group had a return on equity of 3.39% and a net margin of 3.19%. The firm had revenue of $455.86 million during the quarter, compared to the consensus estimate of $431.59 million. The firm’s quarterly revenue was up 25.3% compared to the same quarter last year. Equities analysts forecast that LifeStance Health Group will post 0.16 EPS for the current fiscal year.

Insider Buying and Selling

In other LifeStance Health Group news, COO Lisa K. Miller sold 47,912 shares of the business’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $10.85, for a total value of $519,845.20. Following the completion of the transaction, the chief operating officer directly owned 281,289 shares in the company, valued at approximately $3,051,985.65. The trade was a 14.55% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CTO Vukasin Paunovich sold 42,067 shares of the stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $12.87, for a total value of $541,402.29. Following the transaction, the chief technology officer directly owned 205,379 shares in the company, valued at approximately $2,643,227.73. This represents a 17.00% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 13,777,580 shares of company stock worth $146,433,781. 3.50% of the stock is owned by insiders.

Institutional Investors Weigh In On LifeStance Health Group

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. BlackRock Inc. purchased a new position in LifeStance Health Group during the second quarter worth about $389,293,000. Wellington Management Group LLP acquired a new stake in LifeStance Health Group in the 2nd quarter worth about $30,881,000. Jennison Associates LLC boosted its stake in LifeStance Health Group by 38.5% in the 1st quarter. Jennison Associates LLC now owns 10,228,801 shares of the company’s stock worth $65,157,000 after buying an additional 2,843,388 shares during the last quarter. Dimensional Fund Advisors LP grew its holdings in LifeStance Health Group by 16.4% in the 1st quarter. Dimensional Fund Advisors LP now owns 10,367,680 shares of the company’s stock valued at $66,038,000 after buying an additional 1,461,215 shares during the period. Finally, Bank of America Corp DE purchased a new stake in LifeStance Health Group in the 2nd quarter valued at about $14,987,000. Hedge funds and other institutional investors own 85.50% of the company’s stock.

Key Stories Impacting LifeStance Health Group

Here are the key news stories impacting LifeStance Health Group this week:

• Positive Sentiment: BTIG Research raised its price target to $20 from $18 and maintained a Buy rating. The new target implies 48.7% upside from the cited $13.45 share price. Article: LifeStance Health Group Stock Price Target Raised at BTIG Research
• Positive Sentiment: LifeStance reported third-quarter adjusted earnings of $0.06 per share, beating estimates of $0.04, and revenue of $455.9 million, above the $431.6 million consensus. Revenue increased 25.3% year over year, and the company raised its full-year outlook—supporting investor optimism about growth and profitability. Article: LifeStance Reports Strong Third Quarter 2026 Financial Results and Raises Full Year Outlook

LifeStance Health Group Company Profile

LifeStance Health Group, Inc is a provider of outpatient behavioral health services in the United States. Through a network of clinicians and care centers, the company offers mental health care through in-person appointments and telehealth visits.

LifeStance’s services include individual, couples and family therapy; psychiatric evaluation and medication management; psychological and neuropsychological testing; and treatment for conditions such as depression, anxiety, attention-deficit/hyperactivity disorder, bipolar disorder, post-traumatic stress disorder and other behavioral health concerns.